Endocrinology and Metabolism10.3803/enm.2020.7812021361157-170Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse ModelJin Hee Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Lim,,
Endocrinology and Metabolism10.3803/enm.2021.109202136157-59Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 DiabetesJang Won Son,,
Diabetes10.2337/db13-07102013631101-110Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor–Deficient MiceBilal A. Omar, Birgitte Andersen, Jacob Hald, Kirsten Raun, Erica Nishimura, Bo Ahrén,
Diabetes, Obesity and Metabolism10.1111/dom.146402022245788-805Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetesChristophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal,,
Atherosclerosis10.1016/j.atherosclerosis.2015.04.89820152411e178-e179Effects of body weight reduction on plasma fibroblast growth factor 21 in obese patients with type 1 diabetes mellitusF. Musil, V. Blaha, A. Ticha, R. Hyspler, M. Haluzik, J. Lesna, A. Smahelova, L. Sobotka,
Diabetes10.2337/db18-2231-pub201867Supplement_1Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) PatientsSASAN FAZELI, NICOLE EHRHARDT,
Diabetic Medicine10.1111/j.1466-5468.2004.1180h.x200421s118-20Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of Type 2 diabetesJ. Rachman,
Atherosclerosis10.1016/j.atherosclerosis.2018.06.4492018275e151Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2).M. Walus-miarka, B. Idzior-Walus, M. Kapusta, A. Trojak, P. Miarka, M.T. Malecki,
Diabetes10.2337/db18-166-or201867Supplement_1Serum Fibroblast Growth Factor-21 Is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Incident Atherosclerotic Cardiovascular DiseasesLIANG WU, LINGLING QIAN, HUATING LI, WEIPING JIA,
Diabetes mellitus10.14341/dm96232018214293-300Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetesNina A. Petunina, Milena Е. Telnova,